trending Market Intelligence /marketintelligence/en/news-insights/trending/vcwwckeuuhy82avjwugfea2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Impax shareholders approve merger with Amneal Pharmaceuticals

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Impax shareholders approve merger with Amneal Pharmaceuticals

Impax Laboratories Inc.'s stockholders approved the company's merger with Amneal Pharmaceuticals LLC.

The shareholder approval was one of the requirements for the closing of the deal, which is expected to occur during the second quarter.

The closing of the transaction remains subject to certain regulatory approvals and satisfaction of customary closing conditions.

Impax and Amneal are merging in an all-stock transaction, in which Amneal Holdings members will own about 75% of the new company's shares and Impax shareholders will own about 25%.

The combined company will be called Amneal Pharmaceuticals Inc.